ClinicalTrials.gg
Not yet recruitingNCT07950163ASCLEPIUSUpdated Nov 20, 2026

Paired Associative Stimulation of the Motor Cortex and the Dorsal Roots of the Cervical Spine for the Recovery of Arm and Hand Function in Chronic Middle Cerebral Artery Stroke. ASCLEPIUS Safety Evaluation Pilot Study

An interventional study of Epidural paired associative stimulation of the motor cortex and cervical dorsal roots and Sham epidural stimulation in Stroke, Infarction, Middle Cerebral Artery and Hemiparesis, sponsored by Juan Antonio Barcia Albacar. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Primary conditionInfarction, Middle Cerebral ArteryRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Infarction, Middle Cerebral Artery
Why
  1. The study's listed conditions name Infarction, Middle Cerebral Artery, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Juan Antonio Barcia Albacar · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Study summary

The goal of this pilot clinical trial is to learn whether paired associative stimulation (PAS) of the primary motor cortex and the cervical spinal dorsal roots, delivered through implanted epidural electrodes and combined with neurorehabilitation, is safe in adults with chronic paresis or paralysis of the arm and hand after a stroke in the territory of the middle cerebral artery.

The main question it aims to answer is:

* What adverse events occur during 12 months of follow-up with this treatment?

Secondary questions are whether the stimulation is feasible (whether pairing the corresponding electrode contacts of the motor cortex and the cervical spinal cord increases the motor response to stimulation) and whether it shows preliminary signs of efficacy on upper limb motor function, quality of life and caregiver burden.

Researchers will compare PAS plus rehabilitation with sham stimulation plus rehabilitation during a two-month double-blind phase.

Participants will:

  • Have epidural electrodes surgically implanted over the primary motor cortex and the cervical spinal cord, connected to an implanted pulse generator
  • Receive PAS or sham stimulation together with rehabilitation sessions for two months
  • If assigned to sham stimulation, receive open-label PAS plus rehabilitation for a further two months
  • Attend follow-up visits for 12 months
Read the detailed description

Stroke in the territory of the middle cerebral artery (MCA) commonly leads to a chronic upper limb motor syndrome with loss of strength, reduced dexterity, abnormal synergies and spasticity. Paired associative stimulation (PAS) modulates synaptic connectivity following Hebbian principles: depending on the time interval between two paired stimuli, corticospinal connectivity can be strengthened or weakened. The hypothesis of this study is that invasive paired electrical stimulation of the primary motor cortex (M1) and the cervical spinal dorsal roots, applied together with neurorehabilitation, can be delivered without causing adverse effects by itself, and may produce a more consistent and longer-lasting effect than non-invasive approaches.

This is a single-center, prospective, randomized, controlled, two-phase pilot study (safety and exploratory therapeutic study) in 12 patients with chronic MCA stroke (6 experimental, 6 control), randomized 1:1 in balanced blocks of four.

All participants undergo surgery under general anesthesia. An epidural paddle lead (Artisan MRI Surgical Lead, Boston Scientific) is placed over M1, guided by intraoperative neurophysiology, and two epidural percutaneous leads (Linear Lead, Boston Scientific) are placed over the posterior aspect of the cervical spinal cord from spinal segments C3 to T1, as lateral as possible towards the dorsal roots of the affected side. Leads are initially externalized for postoperative neurophysiological studies (EMG responses to stimulation of each contact) so that cortical and cervical contacts acting on the same muscle groups can be paired. Within one week, the leads are tunneled and connected to an implanted 32-contact pulse generator (WaveWriter Alpha, Boston Scientific). The devices are CE-marked and are used in this study outside their intended purpose.

After a postoperative recovery period of about one month, the generator is programmed. In Phase I (two months, double-blind), the experimental group receives PAS and the control group receives sham stimulation (non-effective settings of the spinal lead that may produce a subjective sensation but no motor response), both combined with the same neurorehabilitation program (physiotherapy and occupational therapy, two or three sessions per week on alternate days). Stimulation settings are reviewed weekly. Participants and the outcome assessor are blinded; the neurosurgical team and the investigator who programs the device are not. In Phase II (two months, open-label), control group participants receive PAS plus rehabilitation.

Follow-up is identical in both groups: weekly during the two months of each stimulation phase, then monthly until month 6 and quarterly until month 12 after surgery. Brain MRI and neurophysiological assessment are performed before surgery, at the end of the stimulation period and at the end of follow-up. After 12 months, the system may be explanted if it provides no clinical benefit and according to the patient's wishes.

An independent Data Monitoring Committee reviews adverse events and other study data after the first patient and after the fourth patient complete their stimulation phase(s), before further patients are included.

Given the pilot nature and sample size, the analysis is descriptive and exploratory; no formal hypothesis test of efficacy is planned.

02

Conditions studied

  • Stroke
  • Infarction, Middle Cerebral Artery
  • Hemiparesis
  • Upper Extremity Paresis

Browse trials for

Keywords

  • Paired associative stimulation
  • Epidural motor cortex stimulation
  • Cervical spinal cord stimulation
  • Neurorehabilitation
  • Chronic stroke
  • Upper limb motor recovery
03

In context

Infarction, Middle Cerebral Artery Reclassified

41 studies on the registry are indexed under Infarction, Middle Cerebral Artery; 7 are open to participants now.

This study's planned enrollment of 12 is below the median of 40 across 33 interventional studies indexed under Infarction, Middle Cerebral Artery.

Browse Infarction, Middle Cerebral Artery studies →

Lead sponsor

This is the only study on the registry with Juan Antonio Barcia Albacar as lead sponsor.

Compared within Infarction, Middle Cerebral Artery, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Older than 18 and younger than 85 years of age.
  • Single ischemic or hemorrhagic stroke with more than 6 months of evolution, with involvement of the hand and arm, that has shown no improvement with standard treatment after two previous reviews.
  • No intercurrent strokes.
  • Moderate functional impairment on the Fugl-Meyer Assessment for Upper Extremity (FMA-UE score 20 to 49).
  • Good trunk control.
  • Meets the safety requirements for imaging studies.
  • Cooperative.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Severe disease or disorder (e.g., cancer, severe cardiac or respiratory disease, renal failure) or cognitive impairment ( \< 24), visual impairment or language impairment that could affect the ability to participate in a rehabilitation program.
  • Presence of any previously implanted medical device.
  • Severe claustrophobia.
  • Major depression or any emotional disorder with a severe deficit of attention or cooperation that could cause difficulty in hand function.
  • Modified Ashworth Scale score of 3 or higher.

Withdrawal criterion after enrollment: absence of evidence of partial preservation of the affected corticospinal tract on MRI tractography or neurophysiological testing (motor evoked potentials by transcranial magnetic stimulation).

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Paired associative stimulation plus rehabilitation

    Surgical implantation of an epidural lead over the primary motor cortex and two epidural leads over the cervical spinal cord, connected to an implanted pulse generator. During Phase I (2 months, starting about one month after surgery), participants receive paired associative stimulation (PAS) of the motor cortex and cervical dorsal roots during neurorehabilitation sessions (2 or 3 sessions per week). Stimulation settings are reviewed weekly.

    Device: Epidural paired associative stimulation of the motor cortex and cervical dorsal roots · Other: Neurorehabilitation

  • Sham comparator
    Sham stimulation plus rehabilitation, then open-label PAS

    Same surgical implantation as the experimental arm. During Phase I (2 months, starting about one month after surgery), participants receive sham stimulation (non-effective settings of the spinal lead that may produce paresthesia but no motor response) during the same neurorehabilitation program and visit schedule. After Phase I, participants enter Phase II (2 months, open-label) and receive paired associative stimulation (PAS) plus rehabilitation.

    Device: Epidural paired associative stimulation of the motor cortex and cervical dorsal roots · Device: Sham epidural stimulation · Other: Neurorehabilitation

Interventions

  • DeviceEpidural paired associative stimulation of the motor cortex and cervical dorsal roots

    Paired associative stimulation (PAS) delivered through an implanted 32-contact pulse generator (WaveWriter Alpha, Boston Scientific) connected to an epidural lead over the primary motor cortex (Artisan MRI Surgical Lead) and two epidural leads over the cervical spinal cord, C3 to T1, placed laterally towards the dorsal roots of the affected side (Linear Lead). Cortical and cervical contacts that evoke responses in the same muscle group are paired, with an inter-stimulus delay derived from the EMG response latencies of each contact. Stimulus intensity is set immediately below the threshold for a motor response. Stimulation is applied during rehabilitation sessions and adjusted weekly for two months. The devices are CE-marked and used outside their intended purpose.

  • DeviceSham epidural stimulation

    Same implanted system as in the experimental arm. The pulse generator is programmed with settings that are not effective for inducing paired associative stimulation: stimulation of a single contact of the spinal lead with settings that produce paresthesia but no motor response. Sham stimulation is applied during rehabilitation sessions and reviewed weekly for two months, with the same visit schedule as the experimental arm.

  • OtherNeurorehabilitation

    Multidisciplinary neurorehabilitation program for the affected upper limb combining physiotherapy and occupational therapy, delivered two or three days per week on alternate days according to clinical status and tolerance, during the stimulation phases. The program is identical in both arms and is delivered by rehabilitation staff blinded to group allocation during Phase I.

06

What researchers measure

Primary outcomes

  1. Cumulative incidence of adverse events

    Number of participants with adverse events, including those observed by the research team and those spontaneously reported by the participant, classified as serious or non-serious, by intensity (grades derived from CTCAE) and by causal relationship to the investigational device, the procedure or the stimulation. Expected undesired effects include pain, spasticity, muscle strength or sensation worse than at baseline, blocking of movements due to antagonist muscle contraction, worsening of hand dexterity and any other subjective intolerance.

    Time frame: From surgery to 12 months after hospital discharge

Secondary outcomes

  1. Feasibility: change in the amplitude of the motor response evoked by stimulation after paired associative stimulation

    Ability to produce an increase in the EMG motor response to single stimulation of the primary motor cortex or the cervical spinal cord after pairing the corresponding electrode contacts, compared with the response evoked without paired associative stimulation.

    Time frame: Postoperative neurophysiological assessment, month 3 (end of Phase I), month 5 (end of Phase II, control group only) and month 12 after hospital discharge

  2. Change in Fugl-Meyer Assessment for Upper Extremity (FMA-UE) score

    Motor impairment of the affected upper limb. Total score ranges from 0 to 66; higher scores indicate better motor function.

    Time frame: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge

  3. Change in Action Research Arm Test (ARAT) score

    Functional capacity of the affected upper limb (grasp, grip, pinch and gross movement). Total score ranges from 0 to 57; higher scores indicate better function.

    Time frame: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge

  4. Change in Chedoke Arm and Hand Activity Inventory score

    Functional ability of the affected arm and hand in bilateral activities of daily living. Higher scores indicate greater functional independence.

    Time frame: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge

  5. Change in Upper Limb Functional Index score

    Patient-reported functional status of the upper limb.

    Time frame: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge

  6. Change in QuickDASH score

    Patient-reported upper limb disability and symptoms. Score ranges from 0 to 100; higher scores indicate greater disability.

    Time frame: Every 2 weeks during Phase I (month 1 + 2 weeks to month 3 after hospital discharge) and, in the control group only, every 2 weeks during Phase II (month 3 + 2 weeks to month 5)

  7. Change in Motor Activity Log (MAL) score

    Patient-reported amount and quality of use of the affected arm in daily activities. Item scores range from 0 to 5; higher scores indicate more and better use of the arm.

    Time frame: Weekly during Phase I (month 1 + 1 week to month 3 after hospital discharge) and, in the control group only, weekly during Phase II (month 3 + 1 week to month 5)

  8. Change in Modified Ashworth Scale (MAS) score

    Spasticity of the affected upper limb. Scores range from 0 to 4; higher scores indicate greater spasticity.

    Time frame: Month 2 and month 3 after hospital discharge (Phase I) and, in the control group only, month 4 and month 5 (Phase II)

  9. Change in Modified Tardieu Scale (MTS)

    Spasticity of the affected upper limb, assessed by the quality of the muscle reaction and the angle of muscle reaction to passive stretch.

    Time frame: Month 1 (start of Phase I), month 3 (end of Phase I) and, in the control group only, month 5 (end of Phase II) after hospital discharge

  10. Goal Attainment Scaling (GAS)

    Attainment of individualized rehabilitation goals. Each goal is rated from -2 to +2; higher scores indicate better goal attainment.

    Time frame: Month 1, month 3, month 5 (control group only), month 6 and month 12 after hospital discharge

  11. Change in modified Rankin Scale (mRS) score

    Global disability. Scores range from 0 (no symptoms) to 6 (death); higher scores indicate greater disability.

    Time frame: Baseline (before surgery), month 6 and month 12 after hospital discharge

  12. Change in perceived health-related quality of life (EuroQol 5D)

    Health-related quality of life perceived by the participant, measured with the EuroQol 5D questionnaire.

    Time frame: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge

  13. Change in caregiver burden (reduced Zarit questionnaire)

    Burden of the main caregiver, measured with the reduced Zarit Burden Interview. Higher scores indicate greater burden.

    Time frame: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 20, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07950163
Lead sponsor
Juan Antonio Barcia Albacar
Responsible party
Juan Antonio Barcia Albacar (Principal Investigator, Hospital San Carlos, Madrid) — Sponsor-investigator
First posted
Nov 20, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Juan Antonio Barcia Albacar
Contact
jabarcia@ucm.es
+34 917043744
Juan Antonio Barcia Albacar
principal investigator · Servicio de Neurocirugía, Hospital Clínico San Carlos

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion